Latest news

• Roche sets disruptive price for new MS drug Ocrevus in US

  Ocrevus' clinical profile has already caught the attention of MS patients and their doctors, with trials showing that the drug outperformed Merck KGaA's Rebif (interferon beta-1a) in two relapsing

• Avelumab costs peg back profit at Merck KGaA

  Pfizer-partnered avelumab is central to Merck's plans to revitalise its healthcare business, currently under pressure as top-selling Rebif (interferon beta-1a) - an injectable treatment for multiple sclerosis - tries

• FDA delays verdict on Roche's MS drug Ocrevus

  Ocrevus is the first investigational medicine with the potential to treat both forms, outperforming Merck KGaA's Rebif (interferon beta-1a) in the two relapsing multiple sclerosis phase III trials and

• Merck's pharma unit faces tougher 2017 as fertility boost recedes

  2017". That's important because Gonal-f has buoyed Merck's healthcare unit in the face of declining sales for its two biggest products - injectable multiple sclerosis therapy Rebif (interferon ... 1a) and colorectal cancer therapy Erbitux (cetuximab) -

• Fertility drugs drive healthcare growth at Merck KGaA

  Merck makes the most of its portfolio of mature drugs, and top-seller Rebif (interferon beta-1a) for relapsing-remitting multiple sclerosis held up fairly well despite fierce competition from newer,